An unprecedented pace of research is driving new treatment approaches for patients with melanoma, lung, and blood cancers as well as chronic diseases like cystic fibrosis and diabetes. Personalized medicine, molecularly targeted drugs and immunotherapies are yielding better outcomes. Even the most cautious researchers and physicians are starting to use the word "cure" in some situations. But access to innovation can be limited. The cost to create these breakthrough drugs threatens to break the innovators who develop them as well as the entities that pick up the tab. How are new medicines integrated into standard-of-care to ensure all patients have equal access to the most promising treatments? What are the barriers and what do they mean for patients and their doctors? This panel will discuss the challenge and also consider ways that next-generation science and innovative policies can be leveraged to make the best treatments available to patients.

Moderator: Louise M. Perkins
Speakers: Gideon Bollag, Wyatt Decker, Jill DeSimone, Omid Hamid, Daniel Hilferty